Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up

Carly Harrison¹, Rashmi Sinha², Emily Sirotich³, Naira Ikram⁴, Kristen Young⁵, Christele Felix¹, Karen Durrant⁶, Richard Beesley⁷, Serena Mingolla⁸, Ana Isabel Martín Mancheño⁹, Dawn Richards¹⁰, Evelyn Olmedo¹¹, Wendy Costello¹², Monique Gore-Massy¹³, Laurie Proulx¹⁴, Maria Marino¹⁵ and Richard Howard¹⁶, ¹LupusChat, New York, NY, ²Systemic JIA Foundation, Cincinnati, OH, ³LA Lupus Lady, Hamilton, ON, Canada, ⁴Duke University, Austin, TX, ⁵Phoenix, AR, ⁶Autoinflammatory Alliance, San Francisco, CA, ⁷Juvenile Arthritis Research, United Kingdom, ⁸Associazione Nazionale Persone con Malattie Reumatolgiche e Rare APMARR APS, Brindisi, Italy, ⁹CEADE, Madrid, Spain, ¹⁰Canadian Arthritis Patient Alliance, Toronto, ON, Canada, ¹¹Buenos Aires, El Salvador, ¹²iCAN, Bansha, Tipperary, Ireland, ¹³Lupus Foundation of America, Brooklyn, NY, ¹⁴Canadian Arthritis Patient Alliance, Ottawa, ON, Canada, ¹⁵Arthritis Foundation; Vectra, Athens, GA, ¹⁶Spondylitis Association of America, Van Nuys, CA

Meeting: ACR Convergence 2020

Keywords: Patient reported outcomes

Session Information

Date: Sunday, November 8, 2020

Title: Patient Perspectives Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The COVID-19 Global Rheumatology Alliance (GRA) is a volunteer-driven organization that originated in response to the global pandemic. It was created to improve patient care, by collecting and disseminating information about the impact of COVID-19 on rheumatic disease. From the very beginning GRA involved patients in its activities.

Intervention:

GRA was conceptualized in Twitter discussions between rheumatologists and patient representatives. More were invited to join through social media and patient organizations. A diverse group of patients from across the world, representing many rheumatic diseases, both adult and pediatric ended up joining the effort.

GRA involves patients at all levels of the organization, while Slack channels promote open communication between patients and researchers.

Maintenance:

Collecting and Disseminating Data

A key way that GRA collects information is through its Patient Experience Survey. The goal of this anonymous survey is to understand patients’ experiences managing their care during COVID-19. Representatives actively collaborated with researchers to create the survey, translate it into 9 languages, and distribute to patient groups and promote on social media.

Accessible Scientific Information

Every GRA publication is summarized into lay summaries written in non-technical language. Patients help in creating and then disseminating these summaries back to their patient groups and broader networks on social media.

Patient Representation in Organizational Structure

Patient representation is reflected in several ways: (a) two patient representatives on the steering committee, (b) a patient board that serves as a conduit between the broader patient community and GRA steering committee, and (c) three teams led by patients. The research team coordinates and develops research initiatives, the resources team compiles and shares resources, and the communications team disseminates relevant information to the broader community.

Open Communication Channels

Global communication within GRA is facilitated by the use of open, asynchronous Slack channels enabling collaborationbetween the teams, researchers, and patient representatives.

Quality of Life:

The collective impact of these patient engagement efforts has been positive. Considering GRA was founded in March 2020, there are many areas for growth, and as needs are identified, GRA tries to quickly address them by creating new patient roles. While many organizations are either centered around researchers or patients, GRA uniquely facilitates collaboration and conversation between both sides, serving as a model to involve patients from the ground up.

Figure 1: Patient involvement in GRA in numbers

Disclosure: C. Harrison, Aurinia Pharmaceuticals Inc, 5, Astra Zeneca Pharmaceuticals, 5; R. Sinha, None; E. Sirotich, None; N. Ikram, None; K. Young, None; C. Felix, CISCRP, 9, Lupus Therapeutics, 9, Astrazeneca, 5, Aurinia, 5; K. Durrant, None; R. Beesley, None; S. Mingolla, None; A. Martín Mancheño, None; D. Richards, Eli Lilly Canada, 8, Various companies, 9; E. Olmedo, None; W. Costello, None; M. Gore-Massy, Aurinia Pharmaceuticals, 5; L. Proulx, None; M. Marino, Vectra, 5; R. Howard, Novartis, 5, AbbVie, 1, Amgen, 1, Bristol-Myers Squibb, 1, GSK, 1, Johnson & Johnson, 1, Eli Lilly, 1, Merck, 1, Novartis, 1, Pfizer, 1, Teva, 1.

To cite this abstract in AMA style:

Harrison C, Sinha R, Sirotich E, Ikram N, Young K, Felix C, Durrant K, Beesley R, Mingolla S, Martín Mancheño A, Richards D, Olmedo E, Costello W, Gore-Massy M, Proulx L, Marino M, Howard R. Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patient-participation-in-the-covid-19-global-rheumatology-alliance-as-a-model-for-involving-patients-from-the-ground-up/. Accessed .

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-participation-in-the-covid-19-global-rheumatology-alliance-as-a-model-for-involving-patients-from-the-ground-up/